Document:

<PAGE>   1

                                                                   EXHIBIT 10.13

[Note: Asterisks denote material omitted that has been separately filed with the
       SEC pursuant to a request for confidential treatment.]

                        LICENSE AND DEVELOPMENT AGREEMENT

                This License and Development Agreement ("Agreement") is
effective as of November _____, 2000 ("Effective Date") between Combimatrix
Corporation ("Combimatrix"), a Delaware corporation having its principal place
of business at 34395 Southeast Douglas, Suite 110, Snoqualmie, WA 98065, and
Advanced Material Sciences, Inc. ("AMS"), a Delaware corporation having its
principal place of business at 55 South Lake Avenue, Pasadena, California 91101.

1. INTRODUCTION

        1.1 Combimatrix has research, development, and manufacturing
capabilities and facilities, and has developed certain rights relevant to
technology and research related to the Material Sciences field.

        1.2 AMS has research and development capabilities, and facilities to
conduct research and development activities for the development and exploitation
of technology related to the Material Sciences field.

        1.3 Combimatrix and Acacia Research Corporation ("Acacia") entered into
an Investors' Rights Agreement and a Co-Sale Agreement, whereby Acacia
contributed $2 million to the formation of AMS and Combimatrix contributed $1
million to the formation of AMS and agreed that Combimatrix and AMS would enter
into this License and Development Agreement.

        1.4 Combimatrix and AMS desire to enter into this Agreement whereby
Combimatrix will license to AMS all relevant Combimatrix Intellectual Property
for exploitation in the Material Sciences field for the royalty fees specified
herein.

        1.5 In consideration of the mutual covenants and promises contained in
this Agreement, Combimatrix and AMS agree as follows:

2. DEFINITIONS

        2.1 "Improvement Inventions" shall mean all inventions for which patent
applications are or may be filed that are conceived or first reduced to practice
by an employee or contractor of AMS or works that are derivative of works to
which Combimatrix holds the copyright or that incorporate or otherwise expand on
inventions that are subject to Combimatrix Patents and that directly result from
exploitation of the Combimatrix Intellectual Property. It is understood that
inventions or creative works made independently of design or use of Combimatrix
Intellectual Property (such as those inventions made in the course of design or
use of AMS proprietary technologies or other non-Combimatrix technologies) are
not Improvement Inventions within the meaning of this Agreement. Improvement
Inventions shall further not include any other inventions that are conceived of
or reduced to practice by an employee or contractor of a Party.

        2.2 "Combimatrix Patents" means any and all patents or patent
applications (including all divisionals, continuations, continuations-in-part,
reissues, and corresponding foreign patent rights) whose claims would otherwise
be infringed by the making, using,

                                       1
<PAGE>   2

sublicensing or selling of any product developed, licensed, sold, or sublicensed
by AMS in the Material Sciences field.

        2.3 "Combimatrix Intellectual Property" shall mean all Combimatrix
Patents and all other property or rights owned or licensed by Combimatrix that
is subject to copyright, patent, trademark or trade secret protection.

        2.4 "Confidential Information" shall mean all information and materials,
patentable or otherwise, of a Party disclosed by or on behalf of such Party to
the other Party and which creates value for a Party from not being generally
known, including, but not limited to techniques, methodology, equipment, data,
reports, know-how, trade secrets, patent positioning, and business plans,
including any negative developments.

        2.5 "Material Sciences Net Sales" shall mean the aggregate United States
Dollar equivalent of gross revenues received by AMS for or on account of
Material Sciences Products and Services less a) credits or allowances, if any,
actually granted on account of price adjustments, recalls, rejections, or return
of items previously sold, b) prompt payment or actual trade or quantity
discounts actually allowed and taken, c) excises, sales taxes, value added
taxes, consumption taxes, duties, foreign withholding tax actually withheld, or
other taxes imposed upon and paid with respect to such sales (excluding income
or franchise taxes of any kind) and d) insurance and delivery costs actually
incurred. If AMS licenses or sells to or through a distributor, Net Sales shall
be the gross revenues received by AMS from the sale of Material Sciences
Products and Services to such distributor. Any such distributor arrangement must
be under reasonably conventional distributor terms. In the event that AMS sells
or licenses Material Sciences Products or Services to third parties for other
than monetary value in whole or in part, such transfer shall be considered a
license hereunder for accounting and royalty purposes. Net Sales for any such
transfers shall be determined on a country-by-country basis and shall be the
average price of arms length licenses by AMS in such country during the royalty
reporting period in which such transfer occurs, or if no such arms length
licensing occurred in such country during such period, during the last period in
which such arms length sales occurred. If no arms length licenses have occurred
in a particular country, Net Sales for such transfer shall be the average price
of arms length licenses in all countries. If a product that falls within the
definition of Material Sciences Products and Services is sold or licensed as
part of a system, package, or combination product (but not including the sale of
AMS or its assets, in whole or in part), Net Sales shall be calculated by
multiplying the Net Sales of the combination product by the fraction A/B where
"A" is the average unit price of the products when licensed separately and "B"
is the average unit price of the combination product. If the product that falls
within the definition of Material Sciences Products and Services is not licensed
separately, the Parties shall negotiate in good faith the appropriate percentage
of the unit price of the combination product to be assigned.

        2.6 "Material Sciences" shall mean the field of technical, scientific
and engineering specialization focusing on fuel cell catalysts, battery
materials, electronic and electrochemical materials, and all other materials and
products related to the use, storage, conversion and delivery of energy, except
within living or biologic systems. For purposes of this agreement, Materials
Sciences will also mean technology, scientific and engineering specialization
related to

                                       2
<PAGE>   3

sensor arrays where the analyte or analytes of interest are non-biological. For
example, biological entities such as cells, spores, nucleic acids, proteins or
analytes incorporating any of the foregoing are excluded. By way of further
example, analytes within this Material Sciences definition shall include gases,
metal ions, pollutants and chemicals dissolved in condensed phases such as water
or other condensed phases. Material Sciences shall not include any product or
products with medical, clinical or diagnostic applications.

        2.7 "Material Sciences Products and Services" shall mean any product or
service sold by AMS during the Term of this Agreement that is used within or
directly related to the Material Sciences field.

        2.8 "Party" shall mean Combimatrix or AMS. "Parties" shall mean
Combimatrix and AMS.

        2.9 "Services" shall mean the use by a third party of a product or
service that falls within the definition of Material Sciences Products and
Services.

        2.10 "Term" shall mean the period beginning on the Effective Date and
ending on a date twenty (20) years from the Effective Date.

3. INTELLECTUAL PROPERTY

        3.1 Combimatrix shall, upon request by AMS and at AMS's expense,
promptly provide all documentation, whether electronic or reduced to paper,
documenting Combimatrix Intellectual Property that may potentially be exploited
and/or developed by AMS for use in the field of Material Sciences as specified
herein. Combimatrix shall also supply relevant copies of code, prototypes of
devices or other mechanical inventions, assistance and support in the
utilization or comprehension of such supplied information or materials.
Combimatrix shall include in such disclosures all available information about
relevant intellectual property under development. Combimatrix shall continually
inform AMS of all relevant new inventions or developments that may be
appropriately exploited or developed by AMS pursuant to this Agreement on a
timely basis and shall provide all relevant and appropriate information or
materials concerning that invention or development.

        3.2 Combimatrix hereby grants a worldwide, exclusive license to AMS to
use, copy, create derivative works from and otherwise commercially exploit all
relevant Combimatrix Intellectual Property in the field of Material Sciences,
including, without limitation, the right to develop, create, market, license,
sublicense and distribute items based on, incorporating or which would otherwise
infringe Combimatrix Patents. AMS may sublicense to an Affiliated Party any or
all rights held by AMS under this Agreement. For the purposes of this Agreement,
an Affiliated Party shall be defined as a company, corporation or business that
is substantially owned and controlled by the Parties with substantially the same
equity ownership positions as Acacia and Combimatrix hold in AMS at the time of
the formation of the Affiliated Party. AMS may sublicense to any other party any
or all rights held by AMS under this Agreement after AMS obtains Combimatrix'
written approval to such sublicense, which approval shall not be unreasonably
withheld.

                                       3
<PAGE>   4

        3.3 AMS shall own all right, title and interest to Improvement
Inventions developed by it for use in the field of Material Sciences pursuant to
this Agreement. AMS grants to Combimatrix a worldwide, perpetual, non-exclusive
license to use, copy, and otherwise commercially exploit Improvement Inventions
in all fields of use other than Material Sciences. AMS shall be responsible for
the continued prosecution and maintenance of any and all patent applications
related to Improvement Inventions; provided, however, that AMS shall first
consult with Combimatrix as to the preparation, filing, prosecution, and
maintenance of such patent applications and patents and shall furnish to
Combimatrix copies of documents relevant to any such preparation, filing,
prosecution or maintenance. From time to time, Combimatrix may, within its
reasonable discretion, send a written request to AMS specifying that AMS
indicate whether it intends to continue to pay the expense associated with or to
further the prosecution of a patent application related to any Improvement
Invention. If AMS indicates in writing that it does not intend to pay further
expenses or to otherwise take actions to further a specific patent application,
AMS shall take all steps reasonably necessary to transfer the intellectual
property rights associated with the patent application to Combimatrix and to
assist Combimatrix in securing the patent that AMS is abandoning. AMS shall not
be required to transfer the rights necessary to the patent application or to
otherwise assist Combimatrix if AMS, on the advice of counsel, has made a good
faith determination that the patent application will be rejected by the
appropriate reviewing authority.

        3.4 Each party shall promptly notify the other of alleged or threatened
infringement of Improvement Inventions or the other Party's intellectual
property.

4. COMPENSATION

        4.1 AMS shall pay to Combimatrix a royalty fee [****************
******************] within sixty (60) days of the end of each calendar quarter.
[******************************************************************************
***************************************].

        4.2 All payments in this Agreement will be made in the form of a check
or wire transfer to Combimatrix in U.S. Dollars.

        4.3 AMS shall deliver to Combimatrix, within sixty (60) days after the
end of each calendar quarter, a written report showing its computation of
payments due under Section 4.1 of this Agreement. All Net Sales shall be
segmented in each such report according to licenses by AMS on a country by
country basis, including the rates of exchange used to convert such royalties to
U.S. Dollars from the currency in which the licenses were made. For the purposes
of this Agreement, the rates of exchange to be used for converting royalties to
U.S. Dollars shall be those published for the purchase of U.S. Dollars in the
Wall Street Journal for the 15th calendar day of the second month of the quarter
for which payment is due. Simultaneously with the delivery of each such report,
AMS shall tender payment in U.S. Dollars of all royalties shown to be due
therein. Proof of payment shall be secured and sent to Combimatrix as evidence
of such payment in such form as required by the tax authorities having
jurisdiction over AMS. Such taxes shall be deducted from the royalty that would
otherwise be remitted by AMS.

                                       4
<PAGE>   5

5. CONFIDENTIALITY

        5.1 Except to the extent expressly authorized by this Agreement or
otherwise agreed in writing by the Parties, each Party agrees that, for the term
of this Agreement and for five (5) years thereafter or issuance of United States
Letters Patent with respect thereto or publication of a foreign patent
application, whichever is earlier; provided however that information which is
disclosed in writing, or, if disclosed orally, is confirmed within 60 days in
writing, and which is identified in writing as being a trade secret of the
providing party, shall be maintained in secret until such time as it no longer
qualifies as a trade secret or until such time as the providing party advises
the recipient in writing that such information is no longer a trade secret, it
shall keep confidential and shall not publish or otherwise disclose and shall
not use for any purpose other than as provided for in this Agreement any
Confidential Information furnished to it by the other Party pursuant to this
Agreement, except that the foregoing shall not apply to any information that the
receiving Party can demonstrate by competent proof:

                5.1.1 was already known to the receiving Party, other than under
an obligation of confidentiality, at the time of disclosure by the other Party;

                5.1.2 was generally available to the public or otherwise part of
the public domain at the time of its disclosure to the receiving Party;

                5.1.3 became generally available to the public or otherwise part
of the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of such Agreements; or

                5.1.4 was disclosed to the receiving Party, other than under an
obligation of confidentiality to a Third Party, by a Third Party who had no
obligation to the disclosing Party not to disclose such information to others.

        5.2 Each Party may disclose Confidential Information belonging to the
other Party to the extent such disclosure is reasonably necessary for the
following reasons:

                5.2.1 filing or prosecuting patents relating to Improvement
Inventions;

                5.2.2 regulatory filings;

                5.2.3 prosecuting or defending litigation;

                5.2.4 complying with applicable governmental regulations; and

                5.2.5 disclosure to Affiliates or sublicensees who agree to be
bound by similar terms of confidentiality.

        Notwithstanding the foregoing, in the event a Party is required to make
a disclosure of the other Party's Confidential Information pursuant to this
Section 5.2 it will, except where impracticable, give reasonable advance notice
to the other Party of such disclosure and use best

                                       5
<PAGE>   6

efforts to secure confidential treatment of such information. In any event, the
Parties agree to take all reasonable action to avoid disclosure of Confidential
Information hereunder.

        5.3 Combimatrix and AMS shall ensure that each employee, consultant, or
other agent of Combimatrix, AMS or sublicensees who has access to Confidential
Information is bound to obligations of confidentiality and non-use at least
equivalent in scope to those set forth in Sections 5.1 and 5.2.

6. WARRANTY

        6.1 Both Parties to this Agreement represent and warrant that they have
the full right and authority to enter into and perform this Agreement.

        6.2 All Combimatrix Intellectual Property made available by license to
AMS hereunder shall be on an as-is basis. COMBIMATRIX DISCLAIMS ALL
REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED
TO, THE IMPLIED WARRANTIES RELATING TO COMBIMATRIX INTELLECTUAL PROPERTY,
MERCHANTABILITY, AND FITNESS FOR A PARTICULAR PURPOSE. Combimatrix shall have no
liability under any theory of strict liability, negligence, whether active or
passive, or products liability. Combimatrix' entire liability, excluding any
amounts due pursuant to Section 7 of this Agreement, shall in no event exceed
the compensation hereunder. Combimatrix shall have no liability for any
consequential, incidental, or special damages. AMS understands that the risks of
loss herein are reflected in the price of the royalty payments agreed to.

        6.3 All Improvement Inventions made available by license to Combimatrix
hereunder shall be on an as-is basis. AMS DISCLAIMS ALL OTHER REPRESENTATIONS
AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED
WARRANTIES RELATING TO COMBIMATRIX INTELLECTUAL PROPERTY, MERCHANTABILITY, AND
FITNESS FOR A PARTICULAR PURPOSE. AMS makes no warranty that it will exploit or
develop any Combimatrix Intellectual Property. Subject to the terms and
conditions contained elsewhere herein in Section 8.3 of this Agreement. AMS
shall have no liability for consequential, incidental, or special damages.

        6.4 From the time AMS widely offers commercial products related to
Combimatrix Intellectual Property or Improvement Inventions for sale, AMS shall
carry liability insurance in the amount of no less than two million dollars
($2,000,000) per instance to protect Combimatrix from all products liability
claims that could be the subject matter of an indemnification claim hereunder
and AMS shall name Combimatrix as an additional insured party , pay the premiums
therefore, and deliver to Combimatrix, upon request, proof of such insurance.

7. INDEMNITY

        7.1 Combimatrix hereby agrees to indemnify, save, defend, and hold AMS
and its directors, officers, agents, affiliates and related companies and
employees harmless from and against any and all suits, claims, actions, demands,
liabilities, expenses, or loss, including

                                       6
<PAGE>   7

reasonable legal expenses and reasonable attorneys' fees (collectively,
"Claims"), to the extent that such Claim or Claims arise from (i) infringement
of a Third Party's intellectual property relating to the Combimatrix
Intellectual Property, manufacture or manufacturing process, (ii) the negligence
or willful misconduct of Combimatrix, or (iii) Combimatrix' breach or alleged
breach of this Agreement, provided AMS notifies Combimatrix promptly in writing
of the action and gives Combimatrix sole control of the defense, all
negotiations and any settlement, such settlement subject to the written consent
of AMS which shall not be unreasonably withheld. The foregoing indemnities shall
not apply to the extent such Claims are covered by AMS' indemnity set forth in
Section 7.2 below.

        7.2 AMS hereby agrees to indemnify, save, defend, and hold Combimatrix
and its directors, officers, agents, and employees harmless from and against any
and all suits, claims, actions, demands, liabilities, expenses, or loss,
including reasonable legal expenses and attorneys' fees (collectively,
"Claims"), to the extent that such Claim or Claims arise from (i) the claimed
infringement by an Improvement Invention of a Third Party's intellectual
property rights (except to the extent such claimed infringement is solely
related to or concerns Combimatrix Intellectual Property incorporated into or
used in the creation of the Improvement Invention, in which case section 7.1 of
this Agreement applies), (ii) the negligence or willful misconduct of AMS, (iii)
any product liability claims against Combimatrix relating to any products
manufactured, sold or provided by AMS, or (iv) AMS breaches of this Agreement,
provided Combimatrix notifies AMS promptly in writing of the action and gives
AMS sole control of the defense, all negotiations and any settlement such
settlement subject to the written consent of Combimatrix which shall not be
unreasonably withheld. The foregoing indemnities shall not apply to the extent
such Claims are covered by Combimatrix' indemnity set forth in Section 7.1
above.

        7.3 If a Party is entitled to indemnification under either Section 7.1
or 7.2 (the "indemnified Party"), it shall give written notice to the Party
providing indemnification (the "Indemnifying Party") of any claims that may be
subject to indemnification promptly after learning of such claim, and the
Indemnifying Party shall assume the defense of such claims with counsel
reasonably satisfactory to the Indemnified Party. If such defense is assumed by
the Indemnifying Party with counsel so selected, the Indemnifying Party will not
be subject to any liability for any settlement of such claims made by the
Indemnified Party without the Indemnifying Party's consent (but such consent
will not be unreasonably withheld or delayed), and will not be obligated to pay
the fees and expenses of any separate counsel retained by the Indemnified Party
with respect to such claims.

8. TERM AND TERMINATION

        8.1 This Agreement shall be for the Term, unless extended pursuant to
the terms of section 8.2..

        8.2 This Agreement will automatically renew for successive five (5) year
terms unless and until either Party provides written notification of non-renewal
of the Agreement to the other Party at least six (6) months prior to the
expiration of the then current Term or Extended Term. Each such additional five
year period shall be referred to as an Extended Term.

                                       7
<PAGE>   8

        8.3 If AMS does not utilize a discrete and identifiable component or
components of Combimatrix Intellectual Property in the Material Sciences field
within the first two (2) years of the Agreement, Combimatrix may request in
writing that AMS clarify its intention concerning the exploitation of such
property. AMS must respond in writing within thirty (30) days of its request and
provide objective evidence, reasonably satisfactory to Combimatrix, that it has
taken or is about to take steps to utilize such discrete and identifiable
component(s) of Combimatrix Intellectual Property in the Material Sciences
field. If AMS responds that it does not intend to take and is not about to take
steps to utilize such identified Combimatrix Intellectual Property or AMS does
not provide objective evidence, reasonably satisfactory to Combimatrix, that it
has taken or is about to take steps to utilize such discrete and identifiable
component(s) of Combimatrix Intellectual Property in the Material Sciences
field, the Parties shall promptly enter into a written Amendment to this
Agreement amending the license to AMS to such identified Combimatrix
Intellectual Property so that such license is non-exclusive. If the Parties are
unable to reasonably agree on whether AMS has provided such objective evidence
that it has taken or is about to take steps to utilize such discrete and
identifiable component(s) of Intellectual Property, the Parties shall submit the
issue for final and binding determination to a single arbitrator, mutually
acceptable to both Parties and selected by the Parties, who shall operate under
the rules and procedures of the American Arbitration Association. Each Party
shall bear its own expenses associated with the submission of evidence, papers
or the making of appearances before the arbitrator.

        8.4 If either Party alleges that the other Party is in breach of this
Agreement, the Party alleging breach shall identify the breach in writing and
provide the identification to the alleged breaching Party. The Party alleged to
have breached this Agreement shall cure such breach within sixty (60) days. If
such breach remains uncured in the reasonable determination of the Party
alleging one or more breaches of the Agreement, that Party may terminate this
Agreement.

        8.5 Upon termination of this Agreement, the following provisions will
survive: 6, 7, 8 and 10.

9. MISCELLANEOUS

        9.1 AMS shall generate and keep for a period of at least two (2) years
from the date of such generation full, accurate, and true books of accounts and
other records containing all information and data, which may be necessary to
ascertain and verify the fees and royalties payable hereunder. During the Term
of this Agreement and for a period of two (2) years following the time at which
the relevant fee or payment is due, Combimatrix shall have the right from time
to time (not to exceed once during a calendar year) to inspect in confidence, or
have an agent, accountant, or representative inspect in confidence such books,
records, and supporting data. In the event an audit reveals a discrepancy
greater than 10% in the relevant period, AMS will pay any audit fees.

        9.2 Each Party may issue a press release or otherwise disclose to the
public the existence and material terms of this Agreement. The Parties may work
together to coordinate a single release or set of releases acceptable to both
Parties. Other than such initial disclosure, neither Party shall originate any
other news relating to this Agreement without the prior written

                                       8
<PAGE>   9

approval of the other Party, which approval shall not be unreasonably withheld,
or except as otherwise required by law.

        9.3 Either Party may assign any rights or obligations of this Agreement
to a party who acquires all or substantially all of the relevant assets of the
assigning Party by merger or sale of assets or otherwise.

        9.4 This Agreement shall be construed according to the laws of Delaware
without regard to conflict of law provisions.

        9.5 In the event of any controversy or claim relating to, arising out of
or in any way connected to any provision of this Agreement, the Parties shall
first seek to settle their differences amicably between themselves.

        9.6 The waiver by either Party of a breach or a default of any provision
of this Agreement by the other Party shall not be construed as a waiver of any
succeeding breach of the same or any other provision, nor shall any delay or
omission on the part of either Party to exercise or avail itself of any right,
power or privilege that it has or may have hereunder operate as a waiver of any
right, power or privilege by such Party.

        9.7 This Agreement and the documents referred to herein are the full
understanding of the Parties with respect to the subject matter hereof and
supersede all prior understandings and writings relating to the subject matter
herein. No waiver, alteration or modification of any of the provisions herein
shall be binding unless in writing and signed by the Parties.

        9.8 The headings in this Agreement are for convenience only and shall
not be considered in construing this Agreement.

        9.9 In the event that any provision of this Agreement is held by a court
of competent jurisdiction to be unenforceable because it is invalid or in
conflict with any law of any relevant jurisdiction, the validity of the
remaining provisions shall not be affected, and the rights and obligations of
the Parties shall be construed and enforced as if the Agreement did not contain
the particular provision(s) held to be unenforceable.

        9.10 This Agreement shall be binding on and inure to the benefit of the
Parties and their successors and permitted assigns.

        9.11 None of the provisions of this Agreement shall be for the benefit
of or enforceable by any third party.

        9.12 Any notice required under this Agreement shall be made by overnight
mail or courier to the addresses below.

                If to AMS:

                        Advanced Material Sciences, Inc.

                        55 South Lake Avenue

                                       9
<PAGE>   10

                        Pasadena, California 91101

                        If to Combimatrix:

                        Combimatrix Corporation

                        34395 Southeast Douglas

                        Suite 110

                        Snoqualmie, Washington 98065

        9.13 The Parties shall not be liable for delay or nonperformance if
performance is rendered impracticable by the occurrence of any condition beyond
the reasonable control of a Party, if such Party has used reasonable efforts to
avoid such occurrence. Such Party shall give notice to the other Party in
writing promptly, and thereupon the affected Party's performance shall be
excused and the time for performance shall be extended for the period of delay
or inability to perform due to the occurrence.

        9.14 This Agreement may be executed in any number of counterparts, each
of which shall be deemed an original but all of which together shall constitute
one and the same instrument.

                IN WITNESS WHEREOF, the Parties hereto have caused this
Agreement to be executed by their properly and duly authorized officers or
representatives as set forth below.

                  Combimatrix Corporation

                  By:
                      ---------------------------
                  Title:
                         ------------------------
                  Date:
                        -------------------------

                  Advanced Material Sciences, Inc.

                  By:
                      ---------------------------
                  Title:
                         ------------------------
                  Date:
                        -------------------------

                                       10<PAGE>   1
                                                                EXHIBIT 10.13(a)

                           INVESTORS' RIGHTS AGREEMENT

         THIS INVESTORS' RIGHTS AGREEMENT is made as of the ____ day of
November, 2000 (the "Effective Date"), by and among Advanced Material Sciences,
Inc., a Delaware corporation (the "Company"), CombiMatrix Corporation, a
Delaware corporation ("CombiMatrix") and Acacia Research Corporation, a Delaware
corporation ("Acacia"; together with CombiMatrix, the "Investors" each of which
is herein referred to as an "Investor".)

                                    RECITALS

         WHEREAS, in order to induce the Company to approve the issuance of the
Common Stock and to induce the Investors to invest funds in the Company, the
Investors and the Company hereby agree that this Agreement shall govern the
rights of the Investors to cause the Company to register shares of Common Stock
issued or issuable to them and certain other matters as set forth herein;

         NOW, THEREFORE, the parties hereby agree as follows:

1.       Registration Rights.  The Company covenants and agrees as follows:

         1.1 Definitions. For purposes of this Section 1:

             (a) The term "Act" means the Securities Act of 1933, as amended.

             (b) The term "Common Stock" means the Common Stock of the Company,
par value $0.001 per share.

             (c) The term "Common Stock Equivalents" means and includes all
shares of Common Stock issued and outstanding at the relevant time plus (i) all
shares of Common Stock that may be issued upon exercise of any options, warrants
and other rights of any kind that are then exercisable, and (ii) all shares of
Common Stock that may be issued upon conversion or exchange of any convertible
securities which are by their terms then convertible into or exchangeable for
Common Stock, including without limitation, preferred stock.

             (d) The term "Form S-3" means such form under the Act as in effect
on the date hereof or any registration form under the Act subsequently adopted
by the SEC that permits inclusion or incorporation of substantial information by
reference to other documents filed by the Company with the SEC.

             (e) The term "Holder" means any person owning or having the right
to acquire Registrable Securities or any assignee thereof in accordance with
Section 1.11 hereof.

             (f) The term "1934 Act" means the Securities Exchange Act of 1934,
as amended.

                                                   (Investors' Rights Agreement)
<PAGE>   2

             (g) The term "register," "registered," and "registration" refer to
a registration effected by preparing and filing a registration statement or
similar document in compliance with the Act, and the declaration or ordering of
effectiveness of such registration statement or document.

             (h) "Qualified IPO" means the closing of a registered underwritten
public offering of shares of Common Stock
                  of the Company.

             (i) The term "Registrable Securities" means (i) any Common Stock or
Common Stock Equivalents owned by Combimatrix and Acacia and (ii) any Common
Stock or Common Stock Equivalents of the Company issued as (or issuable upon the
conversion or exercise of any warrant, right or other security that is issued
as) a dividend or other distribution with respect to, or in exchange for, or in
replacement of, the shares referenced in (i) above, excluding in all cases,
however, any Registrable Securities sold by a person in a transaction in which
his rights under this Section 1 are not assigned.

             (j) The number of shares of "Registrable Securities" outstanding
shall be determined by the number of shares of Common Stock outstanding that
are, and the number of shares of Common Stock issuable pursuant to then
exercisable or convertible Common Stock Equivalents that are, Registrable
Securities.

             (k) The term "SEC" shall mean the Securities and Exchange
Commission.

         1.2 Request for Registration.

             (a) Subject to the conditions of this Section 1.2, if the Company
shall receive at any time after the earlier of (i) three (3) years after the
date of this Agreement or (ii) six (6) months after the effective date of the
Qualified IPO, a written request from either or both of CombiMatrix and Acacia
(the "Initiating Holders") that the Company file a registration statement under
the Act covering the registration of Registrable Securities with an anticipated
aggregate offering price of at least $7,500,000, then the Company shall, within
twenty (20) days of the receipt thereof, give written notice of such request to
all Holders, and subject to the limitations of this Section 1.2, use all
reasonable efforts to effect, as soon as practicable, the registration under the
Act of all Registrable Securities that the Holders request to be registered in a
written request received by the Company within twenty (20) days of the mailing
of the Company's notice pursuant to this Section 1.2(a).

             (b) If the Initiating Holders intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so
advise the Company as a part of their request made pursuant to this Section 1.2
and the Company shall include such information in the written notice referred to
in Section 1.2(a). In such event the right of any Holder to include its
Registrable Securities in such registration shall be conditioned upon such
Holder's participation in such underwriting and the inclusion of such Holder's
Registrable Securities in the underwriting (unless otherwise mutually agreed by
a majority in interest of the Initiating Holders and such Holder) to the

                                       2           (Investors' Rights Agreement)
<PAGE>   3

extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for such
underwriting by the Company (which underwriter or underwriters shall be
reasonably acceptable to CombiMatrix and Acacia). Notwithstanding any other
provision of this Section 1.2, if the underwriter advises the Company that
marketing factors require a limitation of the number of securities underwritten
(including Registrable Securities), then the Company shall so advise all Holders
of Registrable Securities that would otherwise be underwritten pursuant hereto,
and the number of shares that may be included in the underwriting shall be
allocated to the Holders of such Registrable Securities on a pro rata basis
based on the number of Registrable Securities held by all such Holders
(including the Initiating Holders); provided, however, that the number of shares
of Registrable Securities to be included in such underwriting shall not be
reduced unless all other securities proposed to be included in such underwriting
are first excluded from the underwriting. To facilitate the allocation of shares
in accordance with these promises, the Company may round the number of shares
allocated to any holder to the nearest 100 shares. Any Registrable Securities
excluded or withdrawn from such underwriting shall be withdrawn from the
registration.

             (c) The Company shall not be required to effect a registration
pursuant to this Section 1.2:

                 (i) after the Company has effected three (3) registrations
pursuant to this Section 1.2, and such registration has been declared or ordered
effective excluding any registration in which the number of Registrable
Securities sold by the Initiating Holders is reduced pursuant to Section 1.2(b)
to less than 60% of the number of Registrable Securities originally requested by
initiating Holders to be registered in such offering; or

                 (ii) during the period starting with the date sixty (60) days
prior to the Company's good faith estimate of the date of the filing of, and
ending on a date one hundred eighty (180) days following the effective date of,
a Company-initiated registration subject to Section 1.3, provided that the
Company is actively employing in good faith all reasonable efforts to cause such
registration statement to become effective; or

                 (iii) if the Initiating Holders propose to dispose of
Registrable Securities that may be registered on Form S-3 pursuant to Section
1.4 hereof; or

                 (iv) if the Company shall furnish to Holders requesting a
registration statement pursuant to this Section 1.2, a certificate signed by the
Company's Chief Executive Officer or Chairman of the Board stating that in the
good faith judgment of the Board of Directors of the Company, it would be
detrimental to the Company and its stockholders for such registration statement
to be effected at such time, in which event the Company shall have the right to
defer such filing for a period of not more than one hundred twenty (120) days
after receipt of the request of the Initiating Holders, provided that such right
to delay a request shall be exercised by the Company not more than once in any
twelve (12)-month period.

                                       3           (Investors' Rights Agreement)
<PAGE>   4

         1.3 Company Registration.

             (a) Notice of Registration. If (but without any obligation to do
so) the Company proposes to register (including for this purpose a registration
effected by the Company for stockholders other than the Holders) any of its
stock or other securities under the Act in connection with the public offering
of such securities (other than a registration relating solely to the sale of
securities to participants in a Company stock or other employee benefit plan, a
registration relating to a corporate reorganization or other transaction under
Rule 145 of the Act, a registration on any form that does not include
substantially the same information as would be required to be included in a
registration statement covering the sale of the Registrable Securities, or a
registration in which the only Common Stock being registered is Common Stock
issuable upon conversion of debt securities that are also being registered), the
Company shall, at such time, promptly give each Holder written notice of such
registration. Upon the written request of each Holder given within twenty (20)
days after mailing of such notice by the Company in accordance with Section 3.5,
the Company shall, subject to the provisions of Section 1.3(c), use all
reasonable efforts to cause to be registered under the Act all of the
Registrable Securities that each such Holder has requested to be registered.

             (b) Right to Terminate Registration. The Company shall have the
right to terminate or withdraw any registration initiated by it under this
Section 1.3 prior to the effectiveness of such registration whether or not any
Holder has elected to include securities in such registration. The expenses of
such withdrawn registration shall be borne by the Company in accordance with
Section 1.7 hereof.

             (c) Underwriting Requirements. In connection with any offering
involving an underwriting of shares of the Company's capital stock, the Company
shall not be required under this Section 1.3 to include any of the Holders'
securities in such underwriting unless they accept the terms of the underwriting
as agreed upon between the Company and the underwriters selected by it (or by
other persons entitled to select the underwriters) and enter into an
underwriting agreement in customary form with an underwriter or underwriters
selected by the Company, and then only in such quantity as the underwriters
determine in their sole discretion will not jeopardize the success of the
offering by the Company. If the total amount of securities, including
Registrable Securities, requested by stockholders to be included in such
offering exceeds the amount of securities sold other than by the Company that
the underwriters determine in their sole discretion is compatible with the
success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable Securities,
that the underwriters determine in their sole discretion will not jeopardize the
success of the offering (the securities so included to be first on behalf of the
Company and then to be apportioned pro rata among the selling stockholders
(including the Holders) according to the total amount of securities proposed to
be included therein by each selling stockholder or in such other proportions as
shall mutually be agreed to by such selling stockholders), and if advised by the
underwriters, the selling Holders may be excluded entirely if no other
stockholder's securities are included. To facilitate the allocation of shares in
accordance with these promises, the Company may round the number of shares
allocated to any stockholder to the nearest 100

                                       4           (Investors' Rights Agreement)
<PAGE>   5

shares. For purposes of the preceding parenthetical concerning apportionment,
for any selling stockholder that is a Holder of Registrable Securities and that
is a partnership or corporation, the partners, retired partners and stockholders
of such Holder, or the estates and family members of any such partners and
retired partners and any trusts for the benefit of any of the foregoing persons
shall be deemed to be a single "selling Holder," and any pro rata reduction with
respect to such "selling Holder" shall be based upon the aggregate amount of
Registrable Securities owned by all such related entities and individuals.

         1.4 Form S-3 Registration. In case the Company shall receive from the
Holders of at least ten percent (10%) of the Registrable Securities a written
request or requests that the Company effect a registration on Form S-3 and any
related qualification or compliance with respect to all or a part of the
Registrable Securities owned by such Holder or Holders, the Company shall:

             (a) promptly give written notice of the proposed registration, and
any related qualification or compliance, to all other Holders; and

             (b) use all reasonable efforts to effect, as soon as practicable,
such registration and all such qualifications and compliances as may be so
requested and as would permit or facilitate the sale and distribution of all or
such portion of such Holders' Registrable Securities as are specified in such
request, together with all or such portion of the Registrable Securities of any
other Holders joining in such request as are specified in a written request
given within fifteen (15) days after receipt of such written notice from the
Company, provided, however, that the Company shall not be obligated to effect
any such registration, qualification or compliance, pursuant to this section
1.4:

                 (i) if Form S-3 is not available for such offering by the
Holders;

                 (ii) if the Holders, together with the holders of any other
securities of the Company entitled to inclusion in such registration, propose to
sell Registrable Securities and such other securities (if any) at an aggregate
price to the public (net of any underwriters' discounts or commissions) of less
than $7,500,000;

                                       5           (Investors' Rights Agreement)
<PAGE>   6

                 (iii) if the Company shall furnish to the Holders a certificate
signed by the Chief Executive Officer or Chairman of the Board of the Company
stating that in the good faith judgment of the Board of Directors of the
Company, it would be detrimental to the Company and its stockholders for such
Form S-3 Registration to be effected at such time, in which event the Company
shall have the right to defer the filing of the Form S-3 registration statement
for a period of not more than one hundred twenty (120) days after receipt of the
request of the Holder or Holders under this Section 1.4; provided, however, that
the Company shall not utilize this right more than twice in any twelve month
period;

                 (iv) if the Company has, within the twelve (12) month period
preceding the date of such request, already effected two registrations on Form
S-3 for the Holders pursuant to this Section 1.4; or

                 (v) in any particular jurisdiction in which the Company would
be required to qualify to do business or to execute a general consent to service
of process in effecting such registration, qualification or compliance.

             (c) Subject to the foregoing, the Company shall file a registration
statement covering the Registrable Securities and other securities so requested
to be registered as soon as practicable after receipt of the request or requests
of the Holders. Registrations effected pursuant to this Section 1.4 shall not be
counted as requests for registration effected pursuant to Sections 1.2.

         1.5 Obligations of the Company. Whenever required under this Section 1
to effect the registration of any Registrable Securities, the Company shall, as
expeditiously as reasonably possible:

             (a) prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use all reasonable efforts to cause
such registration statement to become effective, and, upon the request of the
Holders of a majority of the Registrable Securities registered thereunder, keep
such registration statement effective for a period of up to one hundred twenty
(120) days or, if earlier, until the distribution contemplated in the
Registration Statement has been completed;

             (b) prepare and file with the SEC such amendments and supplements
to such registration statement and the prospectus used in connection with such
registration statement as may be necessary to comply with the provisions of the
Act with respect to the disposition of all securities covered by such
registration statement;

             (c) furnish to the Holders such numbers of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of the
Act, and such other documents as they may reasonably request in order to
facilitate the disposition of Registrable Securities owned by them;

                                       6           (Investors' Rights Agreement)
<PAGE>   7

             (d) use all reasonable efforts to register and qualify the
securities covered by such registration statement under such other securities or
Blue Sky laws of such jurisdictions as shall be reasonably requested by the
Holders, provided that the Company shall not be required in connection therewith
or as a condition thereto to qualify to do business or to file a general consent
to service of process in any such states or jurisdictions;

             (e) in the event of any underwritten public offering, enter into
and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering;

             (f) notify each Holder of Registrable Securities covered by such
registration statement at any time when a prospectus relating thereto is
required to be delivered under the Act or the happening of any event as a result
of which the prospectus included in such registration statement, as then in
effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements
therein not misleading in the light of the circumstances then existing;

             (g) cause all such Registrable Securities registered pursuant
hereunder to be listed on each securities exchange on which similar securities
issued by the Company are then listed;

             (h) provide a transfer agent and registrar for all Registrable
Securities registered pursuant hereunder and a CUSIP number for all such
Registrable Securities, in each case not later than the effective date of such
registration;

             (i) furnish, if required by the underwriters or pursuant to an
underwriting agreement, on the date that such Registrable Securities are
delivered to the underwriters for sale in connection with a registration
pursuant to this Section 1, if such securities are being sold through
underwriters, (i) an opinion, dated such date, of the counsel representing the
Company for the purposes of such registration, in form and substance as is
customarily given to underwriters in an underwritten public offering, addressed
to the underwriters and (ii) a letter dated such date, from the independent
certified public accountants of the Company, in form and substance as is
customarily given by independent certified public accountants to underwriters in
an underwritten public offering, addressed to the underwriters; and

             (j) if required by the underwriters or pursuant to an underwriting
agreement, the Company shall make itself available for road shows and due
diligence in such a manner as is customarily given to underwriters in an
underwritten public offering.

         1.6 Information From Holder. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 1 with
respect to the Registrable Securities of any selling Holder that such Holder
shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the

                                       7           (Investors' Rights Agreement)
<PAGE>   8

intended method of disposition of such securities as shall be required to effect
the registration of such Holder's Registrable Securities.

         1.7 Expenses of Registration. All expenses (other than any selling
Holder's pro rata share of underwriting discounts, commissions, out-of-pocket
expenses of selling Holder or Holders and fees and costs of counsel for the
selling Holder or Holders) incurred in connection with registrations, filings or
qualifications pursuant to Sections 1.2, 1.3 and 1,4, including (without
limitation) all registration, filing and qualification fees, printers' and
accounting fees, fees and disbursements of counsel for the Company shall be
borne by the Company. Notwithstanding the foregoing, the Company shall not be
required to pay for any expenses of any registration proceeding begun pursuant
to Section 1.2 if the registration request is subsequently withdrawn at the
request of the Holders of a majority of the Registrable Securities to be
registered (in which case all participating Holders shall bear such expenses pro
rata based upon the number of Registrable Securities that were to be requested
in the withdrawn registration), unless, in the case of a registration requested
under Section 1.2, the Holders of a majority of the Registrable Securities agree
to forfeit their right to one demand registration pursuant to Section 1.2,
provided, however, that if at the time of such withdrawal, the Holders have
learned of a material adverse change in the condition, business, or prospects of
the Company from that known to the Holders at the time of their request and have
withdrawn the request with reasonable promptness following disclosure by the
Company of such material adverse change, then the Holders shall not be required
to pay any of such expenses and shall retain their rights pursuant to Section
1.2.

         1.8 Delay of Registration. No Holder shall have any right to obtain or
seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 1.

         1.9 Indemnification. In the event any Registrable Securities are
included in a registration statement under this Section 1:

             (a) To the extent permitted by law, the Company will indemnify and
hold harmless each Holder, the partners or officers, directors and stockholders
of each Holder, legal counsel and accountants for each Holder, any underwriter
(as defined in the Act) for such Holder and each person, if any, who controls
such Holder or underwriter within the meaning of the Act or the 1934 Act,
against any losses, claims, damages or liabilities (joint or several) to which
they may become subject under the Act, the 1934 Act or any state securities
laws, insofar as such losses, claims, damages, or liabilities (or actions in
respect thereof) arise out of or are based upon any of the following statements,
omissions or violations (collectively a "Violation"): (i) any untrue statement
or alleged untrue statement of a material fact contained in such registration
statement, including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto, (ii) the omission or alleged
omission to state therein a material fact required to be stated therein, or
necessary to make the statements therein not misleading, or (iii) any violation
or alleged violation by the Company of the Act, the 1934 Act, any state
securities laws or any rule or regulation promulgated under the Act, the 1934
Act or

                                       8           (Investors' Rights Agreement)
<PAGE>   9

any state securities laws; and the Company will reimburse each such Holder,
underwriter or controlling person for any legal or other expenses reasonably
incurred by them in connection with investigating or defending any such loss,
claim, damage, liability or action; provided, however, that the indemnity
agreement contained in this subsection l.9(a) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Company (which consent shall
not be unreasonably withheld), nor shall the Company be liable in any such case
for any such loss, claim, damage, liability or action to the extent that it
arises out of or is based upon a Violation that occurs in reliance upon and in
conformity with written information furnished expressly for use in connection
with such registration by any such Holder, underwriter or controlling person;
provided further, however, that the foregoing indemnity agreement with respect
to any preliminary prospectus shall not inure to the benefit of any Holder or
underwriter, or any person controlling such Holder or underwriter, from whom the
person asserting any such losses, claims, damages or liabilities purchased
shares in the offering, if a copy of the prospectus (as then amended or
supplemented if the Company shall have furnished any amendments or supplements
thereto) was not sent or given by or on behalf of such Holder or underwriter to
such person, if required by law so to have been delivered, at or prior to the
written confirmation of the sale of the shares to such person, and if the
prospectus (as so amended or supplemented) would have cured the defect giving
rise to such loss, claim, damage or liability.

             (b) To the extent permitted by law, each selling Holder will
indemnify and hold harmless the Company, each of its directors, each of its
officers who has signed the registration statement, each person, if any, who
controls the Company within the meaning of the Act, legal counsel and
accountants for the Company, any underwriter, any other Holder selling
securities in such registration statement and any controlling person of any such
underwriter or other Holder, against any losses, claims, damages or liabilities
(joint or several) to which any of the foregoing persons may become subject,
under the Act, the 1934 Act or any state securities laws, insofar as such
losses, claims, damages or liabilities (or actions in respect thereto) arise out
of or are based upon any Violation, in each case to the extent (and only to the
extent) that such Violation occurs in reliance upon and in conformity with
written information furnished by such Holder expressly for use in connection
with such registration; and each such Holder will reimburse any person intended
to be indemnified pursuant to this subsection l.9(b), for any legal or other
expenses reasonably incurred by such person in connection with investigating or
defending any such loss, claim, damage, liability or action; provided, however,
that the indemnity agreement contained in this subsection l.9(b) shall not apply
to amounts paid in settlement of any such loss, claim, damage, liability or
action if such settlement is effected without the consent of the Holder (which
consent shall not be unreasonably withheld), provided that in no event shall any
indemnity under this subsection l.9(b) exceed the gross proceeds from the
offering received by such Holder.

                                       9           (Investors' Rights Agreement)
<PAGE>   10

             (c) Promptly after receipt by an indemnified party under this
Section 1.9 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 1.9, deliver to
the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties that may be represented without
conflict by one counsel) shall have the right to retain one separate counsel,
with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such
counsel in such proceeding. The failure to deliver written notice to the
indemnifying party within a reasonable time of the commencement of any such
action, if prejudicial to its ability to defend such action, shall relieve such
indemnifying party of any liability to the indemnified party under this Section
1.9, but the omission so to deliver written notice to the indemnifying party
will not relieve it of any liability that it may have to any indemnified party
otherwise than under this Section 1.9.

             (d) If the indemnification provided for in this Section 1.9 is held
by a court of competent jurisdiction to be unavailable to an indemnified party
with respect to any loss, liability, claim, damage or expense referred to
herein, then the indemnifying party, in lieu of indemnifying such indemnified
party hereunder, shall contribute to the amount paid or payable by such
indemnified party as a result of such loss, liability, claim, damage or expense
in such proportion as is appropriate to reflect the relative fault of the
indemnifying party on the one hand and of the indemnified party on the other in
connection with the statements or omissions that resulted in such loss,
liability, claim, damage or expense, as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties' relative intent,
knowledge, access to information, and opportunity to correct or prevent such
statement or omission.

             (e) Notwithstanding the foregoing, to the extent that the
provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are
in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.

             (f) The obligations of the Company and Holders under this Section
1.9 shall survive the completion of any offering of Registrable Securities in a
registration statement under this Section 1, and otherwise.

                                       10          (Investors' Rights Agreement)
<PAGE>   11

         1.10 Reports Under Securities Exchange Act of 1934. With a view to
making available to the Holders the benefits of Rule 144 promulgated under the
Act and any other rule or regulation of the SEC that may at any time permit a
Holder to sell securities of the Company to the public without registration or
pursuant to a registration on Form S-3, the Company agrees to:

             (a) make and keep public information available, as those terms are
understood and defined in SEC Rule 144, at all times after ninety (90) days
after the effective date of the Qualified IPO;

             (b) file with the SEC in a timely manner all reports and other
documents required of the Company under the Act and the 1934 Act; and

             (c) furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (i) a written statement by the
Company that it has complied with the reporting requirements of SEC Rule 144 (at
any time after ninety (90) days after the effective date of the first
registration statement filed by the Company), the Act and the 1934 Act (at any
time after it has become subject to such reporting requirements), or that it
qualifies as a registrant whose securities may be resold pursuant to Form S-3
(at any time after it so qualifies), (ii) a copy of the most recent annual or
quarterly report of the Company and such other reports and documents so filed by
the Company, and (iii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC that permits the
selling of any such securities without registration or pursuant to such form.

         1.11 Assignment of Registration Rights. The rights to cause the Company
to register Registrable Securities pursuant to this Section 1 may be assigned
(but only with all related obligations) by a Holder to a transferee or assignee
of such securities, provided: (a) the transferee acquires 100% of the
Registrable Securities owned or held by the transferring Holder on the day of
transfer; (b) the Transferee is not eligible to sell the shares pursuant to any
provisions of Rule 144(k) of the Act; (c) the Company is, within a reasonable
time after such transfer, furnished with written notice of the name and address
of such transferee or assignee and the securities with respect to which such
registration rights are being assigned; (d) such transferee or assignee agrees
in writing to be bound by and subject to the terms and conditions of this
Agreement, including without limitation the provisions of Section 1.13 below;
and (e) such assignment shall be effective only if immediately following such
transfer the further disposition of such securities by the transferee or
assignee is restricted under the Act.

         1.12 "Market Stand-Off" Agreement. Each Holder hereby agrees that,
during the period of duration specified by the Company and an underwriter of
common stock or other securities of the Company, following the effective date of
a registration statement of the Company filed under the Act in connection with
an underwritten offering, it shall not, to the extent requested by the Company
and such underwriter, directly or indirectly sell, offer to sell, contract to
sell (including, without limitation, any short sale), grant any option to
purchase or otherwise transfer or dispose of (other than to donees who agree to

                                       11          (Investors' Rights Agreement)
<PAGE>   12

be similarly bound) any securities of the Company held by it at any time during
such period except Common Stock included in such registration; provided,
however, that:

             (a) all officers and directors of the Company and all other persons
with registration rights (whether or not pursuant to this Agreement) enter into
similar agreements; and

             (b) such market stand-off time period shall not exceed 180 days.

         In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to the Registrable Securities of each
Holder (and the shares or securities of every other person subject to the
foregoing restriction) until the end of such period.

         Notwithstanding the foregoing, the obligations described in this
Section 1.12 shall not apply to a registration relating solely to employee
benefit plans on Form S-l or Form S-8 or similar forms which may be promulgated
in the future, or a registration relating solely to a Commission Rule 145
transaction on Form S-14 or Form S-15 or similar forms which may be promulgated
in the future.

         1.13 Damages. The Company recognizes and agrees that the holder of
Registrable Securities will not have an adequate remedy if the Company fails to
comply with this Section 1 and that damages may not be readily ascertainable,
and the Company expressly agrees that, in the event of such failure, it shall
not oppose an application by the holder of Registrable Securities or any other
person entitled to the benefits of this Section 1 requiring specific performance
of any and all provisions hereof or enjoining the Company from continuing to
commit any such breach of this Section 1.

         1.14 Conflict. In the event of a conflict between the provisions of
this Section 1 and an underwriting agreement entered into by the Company and the
holder(s) of Registrable Securities included in a registration pursuant to this
Section 1, the provisions of such underwriting agreement shall control.

         1.15 Termination of Registration Rights. No Holder shall be entitled to
exercise any right provided for in this Section 1 after five (5) years following
the consummation of the Qualified IPO or, as to any Holder, such earlier time at
which all Registrable Securities held by such Holder (and any affiliate of the
Holder with whom such Holder must aggregate its sales under Rule 144) can be
sold in any three (3)-month period without registration in compliance with Rule
144 of the Act.

2.       Covenants of the Company.

         2.1 Delivery of Financial Statements. The Company shall deliver to
CombiMatrix, Acacia, and each Investor owning shares constituting at least 20%
of the Registrable Securities:

             (a) as soon as practicable, but in any event within ninety (90)
days after the end of each fiscal year of the Company, an income statement for
such fiscal

                                       12          (Investors' Rights Agreement)
<PAGE>   13

year, a balance sheet of the Company and statement of stockholder's equity as of
the end of such year, and a statement of cash flows for such year, such year-end
financial reports to be in reasonable detail, prepared in accordance with
generally accepted accounting principles ("GAAP"), and audited and certified by
independent public accountants of nationally recognized standing selected by the
Company;

             (b) as soon as practicable, but in any event within forty-five (45)
days after the end of each of the first three (3) quarters of each fiscal year
of the Company, an unaudited income statement, statement of cash flows for such
fiscal quarter and an unaudited balance sheet as of the end of such fiscal
quarter;

             (c) with respect to the financial statements called for in
subsections (a) and (b) of this Section 2.1, an instrument executed by the Chief
Financial Officer or President of the Company certifying that such financials
were prepared in accordance with GAAP consistently applied with prior practice
for earlier periods (with the exception of footnotes that may be required by
GAAP) and fairly present the financial condition of the Company and its results
of operation for the period specified, subject to year-end audit adjustment; and

             (d) budgets of the Company prior to the commencement of a new
fiscal year.

         2.2 Termination of Information Covenants. The covenants set forth in
Section 2.1 shall terminate as to Investors and be of no further force or effect
when the sale of securities pursuant to a registration statement filed by the
Company under the Act in connection with the firm commitment underwritten
offering of its securities to the general public is consummated or when the
Company first becomes subject to the periodic reporting requirements of Sections
13 or 15(d) of the 1934 Act, whichever event shall first occur.

         2.3 Right of First Offer. Subject to the terms and conditions specified
in this Section 2.3, the Company hereby grants to each Investor a right of first
offer with respect to future sales by the Company of its Shares (as hereinafter
defined).

         Subject to the exclusions identified in (i) and (ii) above, each time
the Company proposes to offer any shares of, or securities convertible into or
exercisable for any shares of, any class of its capital stock ("Shares"), the
Company shall first make an offering of Shares to each Investor in accordance
with the following provisions:

             (a) The Company shall mail a notice by certified mail (a "Sale
Notice") to the Investors stating (i) its bona fide intention to offer such
Shares, (ii) the number of such Shares to be offered, and (iii) the price and
terms, if any, upon which it proposes to offer such Shares.

                                       13          (Investors' Rights Agreement)
<PAGE>   14

             (b) By written notification received by the Company within 15
calendar days of the mailing of the Sale Notice, the Investor may elect to
purchase or obtain, at the price and on the terms specified in the Sale Notice,
up to that portion of such Shares which equals the proportion that the number of
shares of Common Stock issued and held, or Common Stock Equivalents then held,
by such Investor bears to the total number of shares of Common Stock of the
Company then outstanding (assuming full conversion and exercise of all
convertible or exercisable securities). The Company shall promptly mail a
written notice by certified mail to each Investor which purchases all the shares
available to it ("Fully-Exercising Investor") of any other Investor's failure to
do likewise. During the ten-day period commencing after such notice is mailed,
each Fully-Exercising Investor shall be entitled to obtain that portion of the
Shares for which Investors were entitled to subscribe but which were not
subscribed for by the Investors which is equal to the proportion that the number
of shares of Common Stock issued and held, or issuable upon conversion of Common
Stock Equivalents then held, by such Fully-Exercising Investor bears to the
total number of shares of Common Stock or Common Stock Equivalents issued and
held, by all Fully-Exercising Investors who wish to purchase some of the
unsubscribed shares.

             (c) If all Shares which Investors are entitled to obtain pursuant
to subsection 2.3(b) are not elected to be obtained as provided in subsection
2.3(b) hereof, the Company may, during the 45 day period following the
expiration of the period provided in subsection 2.3(b) hereof, offer the
remaining unsubscribed portion of such Shares to any person or persons at a
price not less than, and upon terms no more favorable to the offeree than those
specified in the Sale Notice. If the Company does not enter into an agreement
for the sale of the Shares within such period, or if such agreement is not
consummated within 45 days of the execution thereof, the right provided
hereunder shall be deemed to be revived and such Shares shall not be offered
unless first reoffered to the Investors in accordance herewith.

             (d) The right of first offer in this Section 2.3 shall not be
applicable to Shares of Common Stock issued or issuable:

                 (i) upon conversion of any preferred stock of the Company;

                 (ii) pursuant to the acquisition of another corporation or
other entity by the Company by merger, purchase of substantially all of the
assets, or other reorganization approved by the Board of Directors;

                 (iii) to employees, officers, directors, consultants, or other
persons performing services for the Company pursuant to any stock offering,
plan, or arrangement approved by the Board of Directors;

                                       14          (Investors' Rights Agreement)
<PAGE>   15

                 (iv) to financial institutions or equipment lessors in
connection with the extension of credit to the Company or in connection with the
lease of equipment approved by the Board of Directors but not in the aggregate
exceeding 5% of the Company's fully diluted equity provided that in no event
issued for purposes of equity financing;

                 (v) to unaffiliated third parties in connection with
participation in strategic bona fide alliances or other corporate partner
transactions with the Company approved by the Board of Directors; or

                 (vi) pursuant to the acquisition or licenses of technology,
software, or other intellectual property rights approved by the Board of
Directors.

                 (e) The right of first offer set forth in this Section 2.3 may
not be assigned or transferred.

                 (f) The right of first offer set forth in this Section 2.3
shall terminate upon the completion of a Qualified IPO as defined in Section 1.

         2.4 Vesting of Employee Stock and Options. Unless the Board of
Directors of the Company determines otherwise, all Common Stock and options to
acquire Common Stock granted to employees of the Company after the date of this
Agreement shall have a vesting schedule as follows: 12.5% shall vest at the end
of the six month period following full-time employment or the date of the grant,
which ever is later, and the remaining 87.5% shall vest at a rate of 1/10th per
quarter thereafter during the employee's full-time employment.

3.       Voting.

         3.1 Board Composition. During the term of this Agreement and subject to
Section 3.6 hereof and the Company's Certificate of Incorporation (the
"Certificate of Incorporation") and the relevant sections of the Company's
Bylaws (if any), each Investor agrees to vote all Common Stock Equivalents now
or hereafter directly or indirectly acquired (of record or beneficially) by the
Investors, in such manner as may be necessary to elect (and maintain in office)
as members of the Company's Board of Directors, the following individuals:

                 (a) three (3) directors designated by Acacia (each such
director, an "Acacia Designee"); and

                 (b) two (2) directors designated by CombiMatrix (each such
director, a "CombiMatrix Designee").

         For purposes of this Agreement: (i) any individual who is designated
for election to the Company's Board of Directors pursuant to the foregoing
provisions of this Section 3.1 is hereinafter referred to as a "Board Designee";
and (ii) any individual, entity, or group of individuals and/or entities who has
the right to designate one or more Board Designees for election the Company's
Board of Directors pursuant to the

                                       15          (Investors' Rights Agreement)
<PAGE>   16

foregoing provisions of this Section 3.1 is hereinafter referred to as a
"Designator" or as "Designators", as applicable.

         3.2 Board Members. The initial Acacia Designees shall be
[______________], [_____________] and [_____________], the initial CombiMatrix
Designees shall be [______________] and [______________].

         3.3 Changes in Board Designees. From time to time during the term of
this Agreement, a Designator or Designators shall, in their sole discretion,
have the sole right to:

             (a) elect to remove from the Company's Board of Directors any
incumbent Board Designee who occupies a Board seat for which such Designator or
Designators are entitled to designate the Board Designee under Section 3.1;
and/or

             (b) designate a new Board Designee for election to a Board seat for
which such Designator or Designators are entitled to designate the Board
Designee under Section 3.1 (whether to replace a prior Board Designee or to fill
a vacancy in such Board seat); provided, that, such removal and/or designation
of a Board Designee is approved in a writing signed by Designator or Designators
who are entitled to designate such Board Designee under Section 3.1, in which
case such election to remove a Board Designee and/or elect a new Board Designee
will be binding on all such Designators who are entitled to designate such Board
Designee.

         3.4 Further Assurances. The Company agrees not to vote any shares of
Company capital stock, or to take any other actions, that would in any manner
defeat, impair, be inconsistent with or adversely affect the stated intentions
of the parties under Section 3 of this Agreement.

         3.5 Term. The provisions of this Section 3 shall commence upon the
Effective Date and shall terminate upon the first to occur of the following:

             (a) Written agreement of the Investors; or

             (b) Immediately prior to the closing of a Qualified IPO.

4.       Miscellaneous.

         4.1 Successors and Assigns. Except as otherwise provided herein, the
terms and conditions of this Agreement shall inure to the benefit of and be
binding upon the respective successors and assigns of the parties (including
transferees of any shares of Registrable Securities). Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and assigns any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as
expressly provided in this Agreement.

                                       16          (Investors' Rights Agreement)
<PAGE>   17

         4.2 Governing Law. This Agreement shall be governed by and construed
under the laws of the State of Delaware as applied to agreements among Delaware
residents entered into and to be performed entirely within Delaware.

         4.3 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

         4.4 Titles and Subtitles. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

         4.5 Notices. Unless otherwise provided, any notice required or
permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal delivery to the party to be notified or upon
delivery by confirmed facsimile transmission, nationally recognized overnight
courier service, or upon deposit with the United States Post Office, by
registered or certified mail, postage prepaid and addressed to the party to be
notified at the address indicated for such party on the signature page hereof,
or at such other address as such party may designate by ten (10) days' advance
written notice to the other parties.

         4.6 Expenses. If any action at law or in equity is necessary to enforce
or interpret the terms of this Agreement, the prevailing party shall be entitled
to reasonable attorneys' fees, costs and necessary disbursements in addition to
any other relief to which such party may be entitled.

         4.7 Entire Agreement: Amendments and Waivers. This Agreement (including
schedules or exhibits hereto, if any) constitutes the full and entire
understanding and agreement among the parties with regard to the subjects hereof
and thereof and supercedes any prior oral or written understanding. Any term of
this Agreement may be amended and the observance of any term of this Agreement
may be waived (either generally or in a particular instance and either
retroactively or prospectively), only with the written consent of the Company
and the holders of at least seventy five percent (75%) of the Registrable
Securities. Any amendment or waiver effected in accordance with this paragraph
shall be binding upon each holder of any Registrable Securities each future
holder of all such Registrable Securities, and the Company.

         4.8 Severability. If one or more provisions of this Agreement are held
to be unenforceable under applicable law, such provision shall be excluded from
this Agreement and the balance of the Agreement shall be interpreted as if such
provision were so excluded and shall be enforceable in accordance with its
terms.

         4.9 Aggregation of Stock. All shares of Registrable Securities held or
acquired by affiliated entities or persons shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement.

                  [remainder of page intentionally left blank]

                                       17          (Investors' Rights Agreement)
<PAGE>   18

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first above written.

                                          ADVANCED MATERIAL SCIENCES, INC., a
                                          Delaware corporation

                                          By:
                                             -----------------------------------
                                             Name:
                                             Title:

                                          INVESTORS:

                                          ACACIA RESEARCH CORPORATION, a
                                          Delaware corporation

                                          By:
                                             -----------------------------------
                                             Name:
                                             Title:

                                          COMBIMATRIX CORPORATION, a Delaware
                                          corporation

                                          By:
                                             -----------------------------------
                                             Name:
                                             Title:

                                       S-1         (Investors' Rights Agreement)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]